Clinical Edge Journal Scan

Younger age at psoriasis diagnosis or severe disease tied to delayed transition from psoriasis to PsA


 

Key clinical point: Patients with psoriasis were more likely to have a delayed onset of psoriatic arthritis (PsA) if they were diagnosed with psoriasis at a younger age or suffered from severe psoriasis .

Major finding: The median time from psoriasis diagnosis to the incidence of PsA was 35.5 months with age at psoriasis onset (odds ratio [OR] per 10-year decrease 1.63; 95% CI 1.26-2.11) and its severity ( OR for severe vs. mild 3.65; 95% CI 1.18-11.32) being associated with having a psoriasis diagnosis >1 year prior to incident PsA.

Study details: Findings are from a retrospective nested case-control study including 158 patients with incident PsA, of which 41% had concurrent psoriasis and 59% patients had onset of psoriasis before PsA.

Disclosures: This study was funded by the Rochester Epidemiology Project supported by National Institute on Aging, National Center for Advancing Translational Sciences, and others. The authors declared serving as consultants or receiving grants, consulting fees, honoraria, and research support from several sources.

Source: Karmacharya P et al. Semin Arthritis Rheum. 2021;151949 (Dec 31). Doi: 10.1016/j.semarthrit.2021.12.013 .

Recommended Reading

Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indication
MDedge Rheumatology
New option for flares in pustular psoriasis
MDedge Rheumatology
Spesolimab speeds lesion clearance in generalized pustular psoriasis
MDedge Rheumatology
Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
MDedge Rheumatology
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
MDedge Rheumatology
Discontinuing TNF inhibitors may not be required in PsA patients receiving BNT162b2 SARS-CoV-2 vaccine
MDedge Rheumatology
PsA: Upadacitinib shows similar benefits as monotherapy or in combination with nbDMARDs
MDedge Rheumatology
Psoriatic arthritis management should target both clinical and biochemical inflammation
MDedge Rheumatology
Risankizumab shows promise in PsA patients with inadequate response to csDMARDs
MDedge Rheumatology
Dactylitis indicates a more severe disease phenotype in early PsA
MDedge Rheumatology